Presentation is loading. Please wait.

Presentation is loading. Please wait.

Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013.

Similar presentations


Presentation on theme: "Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013."— Presentation transcript:

1 Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013

2 Definition of Evidence-Based Medicine Definition: ▫The integration of individual clinical expertise and the best external evidence when deciding how to care for patients. Pro: ▫Helps clinicians assess whether or not a treatment will help a patient or do more harm Con: ▫Results from studies may not be relevant for all treatment situations and applications

3 Non-Dialysis Chronic Kidney Disease and Iron Deficiency Anemia Iron deficiency is a common cause of anemia in ND-CKD patients Iron deficiency anemia inflicts patients with ND- CKD at all stages Decreased kidney function caused by CKD can cause iron deficiency anemia by: ▫Erythropoietin deficiency  Decreased red blood cell synthesis ▫Decreased use of nutritional and stored iron

4 Qunibi et al., 2010 Studied the efficacy of IV Ferric Carboxymaltose vs Oral Ferrous Sulfate in treating iron deficiency anemia in ND-CKD patients Methods ▫Open-label, randomized, controlled, multicenter trial (47 centers) ▫Subject criteria:   12 years of age, GFR  45 mL/min, Hb  11 g/dL, TSAT  25%, ferritin  300 ng/mL ▫147 people received FCM infusions of a maximum of 1000 mg over 15 mins ▫103 received 325 mg of oral ferrous sulfate 1 hour before meals 3 times daily ▫Study conducted over 8 weeks

5 IV Ferric Carboxymaltose is more effective than Oral Ferrous Sulfate in treating iron deficiency anemia in ND-CKD patients ▫134 from FCM group completed the study (91.2%) ▫84 from oral group completed the study (81.6%) ▫Intravenous FCM was more effective at treating anemia than oral ferrous sulfate ▫FCM increased repletion of iron stores better and faster than oral ferrous sulfate ▫Proportion of a drug-related adverse effects lower in FCM group than oral group Qunibi et al., 2010

6

7 Stancu et al., 2009 Studied the response to IV iron sucrose supplementation in treating iron deficiency anemia in ND-CKD patients Methods ▫3 month-long single center diagnostic study  2 months- admission criteria assessed  Baseline: bone marrow aspiration, TSAT, serum ferritin evaluated ▫Subject criteria:  Hb  11g/dL, Stages 3-5 CKD, GFR  60 mL/min  Excluded if have additional health conditions ▫100 adults (<18) received 1000mg of iron sucrose intravenously 5 days after baseline ▫Returned 1 month later  Evaluated Hb, TSAT, serum ferritin levels

8 Stancu et al., 2009 IV iron supplementation can be useful in managing anemia in ND-CKD patients ▫100% of patients completed study ▫Response defined as  1 g/dL increase in Hb ▫49 responders, 51 nonresponders ▫Mean Hb attained was 10g/dL  1.0 .4 g/dL mean increase ▫Responders were younger and a greater proportion of them were in Stage 4 CKD ▫~1/3 of responders showed iron-replete bone marrow stores

9 Stancu et al., 2009

10 Recommendation and Grades Intravenous iron supplementation is beneficial for ND-CKD patients with iron deficiency anemia Evidence ▫Qunibi et al. = A  Randomized controlled, multicenter trial  Short, no long term effects ▫Stancu et al. = C  Single-center, not randomized controlled  One of the largest studies, however, still relatively small sample size ▫Overall grade = B  Need more long-term studies  More evidence needed in type of IV iron used

11 Bibliography Stancu, S., Barsan, L., Stanciu, A., & Mircescu, G. (2009). Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?. Clinical Journal of the American Society of Nephrology, 5(3), 409-419. Retrieved from http://cjasn.asnjournals.org/content/5/3/409.fullhttp://cjasn.asnjournals.org/content/5/3/409.full Qunibi, W. Y., Martinez, C., Smith, M., Benjamin, J., Mangione, A., & Roger, S. (2010). A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrology Dialysis Transplantation, 26(5), 1599- 1607. Retrieved from http://ndt.oxfordjournals.org/content/26/5/1599.shorthttp://ndt.oxfordjournals.org/content/26/5/1599.short Van Wyck, D. B., Roppolo, M., Martinez, C. O., Mazey, R. M., & McMurray, S. (2005). A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney International, 68(6), 2846-2856. doi:10.1111/j.1523-1755.2005.00758.x


Download ppt "Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013."

Similar presentations


Ads by Google